Epredia’s mission is to improve lives by enhancing cancer diagnostics. The company was established in June 2019 when the PHC Group bought Thermo Fisher Scientific’s anatomical pathology business. Epredia used this spinoff as the catalyst for a global QA and RA transformation. At the time, each of the company’s six manufacturing sites had its own systems and processes, which created needless complexity, inconsistency, and compliance risk that together were causing delays across the product development lifecycle. Epredia’s objective was to move from a mix of aging point solutions to a unified platform that would harmonize quality and regulatory processes globally, reduce waste, and improve efficiency.

Join for free to read